Structure-Activity Relationship of a Novel Group of Mammalian DNA Polymerase Inhibitors, Synthetic Sulfoquinovosyldiacylglycerols

Shinya Hanashima, Yoshiyuki Mizushima, Keisuke Ohta, Takayuki Yamazaki, Fumio Sugawara and Kengo Sakaguchi

Department of Applied Biological Science, Faculty of Science and Technology, Science University of Tokyo, 2641 Yamazaki, Noda, Chiba 278-8510

We reported previously that sulfolipids in the sulfoquinovosyldiacylglycerol class from a fern and an alga are potent inhibitors of DNA polymerase α and β and potent anti-neoplastic agents. In developing a procedure for chemical synthesis of sulfolipids, we synthesized many derivatives and stereoisomers of sulfoquinovosylnonacylglycerol (SQMG)/sulfoquinovosyldiacylglycerol (SQDG). Some of these molecules were stronger inhibitors than the SQMG/SQDG originally reported as natural compounds. In this study, we examined the structure-inhibitory function relationship of synthetic SQMG/SQDG and its relationship to cytotoxic activity. The inhibitory effect is probably mainly dependent on the fatty acid effect, which we reported previously, although each of the SQMG/SQDG was a much stronger inhibitor than the fatty acid alone that was present in the SQMG/SQDG. The inhibitory effect could be influenced by the chain size of fatty acids in the SQMG/SQDG. The sulfate moiety in the quinovose was also important for the inhibition. Lineweaver-Burk plots of SQMG/SQDG indicated that DNA polymerase α was non-competitively inhibited, but the SQMG/SQDG were effective as antagonists of both template-primer DNA-binding and nucleotide substrate-binding of DNA polymerase β. The SQMG had an cytotoxic effect, but the SQDG tested did not. The SQDG might not be able to penetrate into cells. Based on these results, we discuss the molecular action of SQMG/SQDG and propose drug design strategies for developing new anti-neoplastic agents.

Key words: Sulfoquinovosylnonacylglycerol (SQMG) — Sulfoquinovosyldiacylglycerol (SQDG) — DNA polymerase — Enzyme inhibitor — Anti-neoplastic agents

At least seven classes of DNA polymerases (pol. α, β, γ, δ, ε, ζ and η) have been identified in mammalian cells. Moreover, pol. θ may also be expressed in mammals. Recent studies have revealed the biochemical and structural properties of these polymerases, and some of their genes have been cloned. The in vivo functions of some of these polymerases, especially pol. β, δ, ε, ζ and η, appear to be related to DNA repair and/or recombination. On the other hand, pol. α, γ, δ and ε are mainly involved in nuclear or mitochondrial DNA replication. Our recent studies of the polymerases have focused on understanding the structure and function of these polymerases, especially pol. α and β types, and identifying the factors controlling their activities. For these studies, potent and selective inhibitors are required. In screening studies, we found many inhibitors of mammalian DNA polymerases. At present, we are engaged in analyzing the structure and function of the DNA polymerases using these inhibitors from two different viewpoints; to understand the precise role of each polymerase in vivo, and to develop a drug design strategy for cancer chemotherapy agents. Since DNA polymerases are essential enzymes for DNA replication and repair, and thus for cell division, inhibition of the enzymes will lead to killing of cells, especially under conditions of proliferation. The inhibitors of mammalian DNA polymerases are not only molecular tools useful for analyzing the polymerases, but should also be considered as candidates for cancer chemotherapy agents.

Several sulfolipids in the sulfoquinovosyldiacylglycerol class extracted from a fern and an alga were found to be DNA polymerase inhibitors. One of them structurally coincided with a compound from a cyanobacterium reported as an AIDS anti-viral agent. The sulfolipids potently inhibited the activities of mammalian pol. α and β and TdT, and moderately inhibited those of HIV-1 reverse transcriptase in a dose-dependent manner, but hardly influenced the activities of prokaryotic DNA polymerases such as Escherichia coli DNA polymerase I, and DNA metabolic enzymes such as deoxyribonuclease I. Sahara et al. reported that other sulfolipids from sea...
urchin showed anti-tumor activity in studies on transplantation of human tumor into mice.\textsuperscript{22} We recently confirmed that the agents were also mammalian DNA polymerase inhibitors (Mizushima \textit{et al.}, unpublished data). Simbulan \textit{et al.} also showed that several glycolipids from mammals inhibited the activities of mammalian DNA polymerases, and suggested that sulfate and sialic acid moieties in the compounds were essential for the inhibition.\textsuperscript{23} These observations indicated that some of the sulfolipids could be selective inhibitors of mammalian DNA polymerases, and might have potent anti-tumor and/or anti-viral activity. We chemically synthesized natural sulfolipids of the SQMG and SQDG classes, because our experiments required large quantities of the natural sulfolipids, and because stereoisomers of the sulfolipids and their derivatives could be useful as inhibitors. We succeeded in systematically synthesizing many kinds of SQMG/SQDG including stereoisomers of the sulfolipids and their derivatives (Hanashima \textit{et al.}, in preparation). The details of the chemical synthesis of the sulfolipids will be published elsewhere.

In this study, we examined the structure-function relationship for inhibition of DNA polymerases by synthetic derivatives and/or stereoisomers of the SQMG/SQDG, and elucidated the molecular mechanism of the inhibitory action of these synthetic sulfolipids on the DNA polymerase activity and on mammalian cell proliferation. In the SQMG/SQDG, not only the fatty acid moiety, but also the sulfate in the quinovose seem to be important for inhibition of DNA polymerase activity. The molecular mechanism of the inhibition seems to be dependent on the fatty acid chain length, as well as the sulfate moiety in the monosaccharide. This information should allow us to design novel sulfolipid inhibitors.

\textbf{MATERIALS AND METHODS}

\textbf{Chemical synthesis of sulfolipids and their derivatives}

Sulfolipids and their derivatives, including stereoisomers, were synthesized according to a procedure which will be published elsewhere (Hanashima \textit{et al.}, in preparation). Structures of the synthesized compounds are summarized in Fig. 1. We chemically synthesized several types of SQMG and SQDG, and also prepared many compounds by linking a sulfate moiety (group I), monosaccharide (group II), glyceride (group III) and fatty acid(s) (group IV) (see Fig. 1A). In the symbols (e.g. C\textsubscript{18}-α-SQDG), SQDG refers to sulfoquinovosyldiacylglycerol, α refers to the stereoisomer between group II and III, and C\textsubscript{18} refers to C\textsubscript{18}-saturated fatty acid (stearic acid) (see Fig. 1).

\textbf{Enzymes and DNA polymerase assays}

DNA polymerase α (pol. α) was purified from calf thymus by immuno-affinity column chromatography as described previously.\textsuperscript{24} DNA polymerase β (pol. β) was purified from a recombinant plasmid expressing rat pol. β.\textsuperscript{25} \textit{E. coli} DNA polymerase I and human immunodeficiency virus type 1 (HIV-1) reverse transcriptase were purchased from Worthington Biochemical Corp. (Freehold, NJ). T4 DNA polymerase, calf thymus TdT, \textit{Tag} DNA polymerase, T4 DNA polymerase, T7 RNA polymerase and T4 polynucleotide kinase were purchased from TaKaRa (Kyoto). Bovine pancreas deoxyribonuclease I was purchased from Stratagene Cloning Systems (La Jolla, CA).

The activities of DNA polymerases, HIV-1 reverse transcriptase and bovine deoxyribonuclease I were measured by the methods described previously.\textsuperscript{4,5} One unit of DNA polymerase catalyzes the incorporation of 1 mmol of dTTP into synthetic template-primer (poly(dA)/oligo(dT)\textsubscript{12-18}, A/T=2/1) at 37°C in 60 min. The activities of RNA polymerase and polynucleotide kinase were measured in standard assays according to the manufacturer’s specifications, as described by Nakayama and Saneyoshi\textsuperscript{26} and Soltis and Uhlenbeck,\textsuperscript{27} respectively. The activity of bovine deoxyribonuclease I was measured by the methods described previously.\textsuperscript{28}

\textbf{Investigation of cytotoxicity on cultured cells}

For investigation of the \textit{in vivo} effects of SQMG/SQDG, a human stomach cancer cell line originated from a patient with cancer, NUGC-3, was used. The cells were routinely cultured using MEM supplemented with 10% fetal calf serum, 250 mg/ml fungizone, and 300 mg/ml L-glutamine as standard medium, at 37°C in a humidified atmosphere of 5% CO\textsubscript{2}-95% air. Cytotoxicity of SQMG/SQDG was investigated as follows. High concentrations of SQMG and SQDG were dissolved in DMSO and stocked. Approximately 2×10\textsuperscript{4} cells per well were inoculated in 96-well micro plates, then SQMG/SQDG stock solution was diluted to various concentrations with standard medium, and applied to each well. After incubation for 48 h, survival rate was determined by MTT assay.\textsuperscript{29}

\textbf{RESULTS}

\textbf{Inhibitory effects of synthetic SQMG/SQDG on DNA polymerase activities}

The sulfolipids can be separated into four moieties: monosaccharide with or without a sulfate moiety (group I & II), glyceride (group III) and fatty acid(s) (group IV) (Fig. 1). We synthesized new sulfolipids (SQMG/SQDG) (group I & II & III & IV) by assembling derivatives of each of the four parts into different kinds of sulfoquinovosylacylglycerols. The structures of the compounds are summarized in Table I. Some of the compounds, for example the SQMG/SQDG with saturated-form long chain (C\textsubscript{20}- and C\textsubscript{22}-) fatty acids and SQMG/SQDG with unsaturated form fatty acids, were not tested because they have not yet been synthesized. The monosaccharides such as sulfufose and sulforhamnose were used instead of the sulfoquinovose, and the fatty...
acids were saturated species with 14 to 18 carbon atoms. For addition of fatty acids, SQMG/SQDG were synthesized, because these two types of natural product were reported to be effective DNA polymerase inhibitors.\textsuperscript{11, 14, 15)\textsuperscript{2}} The two fatty acid molecules in each SQDG were the same.

As shown in Table I, neither monosaccharides (group II), with or without a sulfate moiety (group I), nor glycerides (group III) showed any inhibitory effect, and the assembled compound, sulfoquinovosylacylglyceride (group I & II & III), also had no inhibitory effect. Each of the fatty acids from C\textsubscript{14} to C\textsubscript{18} (group IV), as described previously,\textsuperscript{4, 6) inhibited the activities of pol.\textsubscript{α} moderately and pol.\textsubscript{β} weakly. When the fatty acid(s) (group IV) were joined to the sulfoquinovosylacylglyceride (group I & II & III) as sulfoquinovosylacylglycerol (group I & II & III & IV), the resultant compound showed a potent inhibitory effect on DNA polymerase activity. The sulfate moiety in the quinovose was essential for inhibition since neutral glycolipids (group II & III & IV) had no inhibitory effect.

For compounds to show potent inhibitory effects, all four parts of the molecule were required. Sulfoquinovose could be replaced with other sulfo-monosaccharides such as sulfofucose and sulforhamnose, although the inhibitory effects of sulfofucosylmonoacylglycerol and the sulforhamnosylmonoacylglycerol were almost the same as that of SQMG. Sulfofucose alone or sulforhamnose alone, like sulfoquinovose, was not capable of inhibiting polymerase activity. SQMG/SQDG must have one or two molecules of fatty acid at the 2\textsuperscript{′} and/or 3\textsuperscript{′} position in the glycerol moiety to inhibit the polymerase-inhibitory activities. Similarly, the SQMG/SQDG could have stereoisomers of two configurations, \textalpha- or \textbeta-type, between the sulfoquinovose (group I & II) and the glyceride (group III). Both of the configuration types inhibited the polymerases to similar extents, suggesting that the configuration is not important for the inhibitory effect. Interestingly, the inhibitory effect was strongly influenced by changes of the sulfolipid structure, suggesting an approach for the design of new SQMG/SQDG.
Table I. Effects of Derivatives and Stereoisomers of Synthesized SQMG/SQDG on the Activities of DNA Polymerase α and β

| Group       | I  | II | Isomer        | IV                | IC_{50} (µM)\(^a\) | MIC (µM)\(^b\) | Symbol          |
|-------------|----|----|---------------|-------------------|---------------------|----------------|-----------------|
|             |    |    | between I and II |                   | Pol. α | Pol. β | Pol. α | Pol. β | Symbol          |
| II          | -  | Quinovose | - | - | >1000 | >1000 |          |        |                |
| II          | -  | Fucose | - | - | >1000 | >1000 |          |        |                |
| II          | -  | Rhamnose | - | - | >1000 | >1000 |          |        |                |
| III         | -  | -  | + | - | >1000 | >1000 |          |        |                |
| IV          | -  | -  | - | Myristic acid (14:0) | 95 | 440 | 180 | >1000 |                |
| IV          | -  | -  | - | Palmitic acid (16:0) | 42 | 290 | 100 | 500 |                |
| IV          | -  | -  | - | Stearic acid (18:0) | 8 | 130 | 35 | 250 |                |
| I&II        | +  | Quinovose | - | - | >1000 | >1000 |          |        |                |
| I&II        | +  | Fucose | - | - | >1000 | >1000 |          |        |                |
| I&II        | +  | Rhamnose | - | - | >1000 | >1000 |          |        |                |
| II&III      | -  | Quinovose | α | + | >1000 | >1000 |          |        |                |
| II&III      | -  | Quinovose | β | + | >1000 | >1000 |          |        |                |
| II&III      | -  | Fucose | α | + | >1000 | >1000 |          |        |                |
| II&III      | -  | Fucose | β | + | >1000 | >1000 |          |        |                |
| II&III      | -  | Rhamnose | α | + | >1000 | >1000 |          |        |                |
| II&III      | -  | Rhamnose | β | + | >1000 | >1000 |          |        |                |
| III&IV      | -  | -  | + | Myristic acid (14:0)/H | 750 | >1000 | >1000 |          |                |
| III&IV      | -  | -  | + | Palmitic acid (16:0)/H | 690 | >1000 | >1000 |          |                |
| III&IV      | -  | -  | + | Stearic acid (18:0)/H | 650 | >1000 | >1000 |          |                |
| III&IV      | -  | -  | + | Myristic acid (14:0)/Myristic acid (14:0) | 550 | >1000 | >1000 |          |                |
| III&IV      | -  | -  | + | Palmitic acid (16:0)/Palmitic acid (16:0) | 470 | >1000 | >1000 |          |                |
| III&IV      | -  | -  | + | Stearic acid (18:0)/Stearic acid (18:0) | 450 | >1000 | >1000 |          |                |
| I&II&III    | +  | Quinovose | α | + | >1000 | >1000 |          |        |                |
| I&II&III    | +  | Quinovose | β | + | >1000 | >1000 |          |        |                |
| I&II&III    | +  | Fucose | β | + | >1000 | >1000 |          |        |                |
| I&II&III    | +  | Fucose | β | + | >1000 | >1000 |          |        |                |
| I&II&III    | +  | Rhamnose | β | + | >1000 | >1000 |          |        |                |
| I&II&III    | +  | Rhamnose | β | + | >1000 | >1000 |          |        |                |
| II&III&IV   | -  | Quinovose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| II&III&IV   | -  | Quinovose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| II&III&IV   | -  | Fucose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| II&III&IV   | -  | Fucose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| II&III&IV   | -  | Rhamnose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| II&III&IV   | -  | Rhamnose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| II&III&IV   | -  | Rhamnose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Quinovose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Quinovose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Quinovose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Quinovose | α | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Quinovose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Quinovose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Fucose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Fucose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Rhamnose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |
| I&II&III&IV | +  | Rhamnose | β | + | Stearic acid (18:0)/H | >1000 | >1000 |        |        |                |

\(a\) 50%-inhibitory concentration.

\(b\) Minimum inhibitory concentration.
Novel Group of DNA Polymerase Inhibitors

The synthetic SQMG/SQDG tended to show stronger effects on pol. α than on pol. β. The activity of pol. α was inhibited potently by the C_{14-18}-SQMG/C_{14-18}-SQDG, and the IC_{50} values (the doses that resulted in inhibition of 50% of the activities) were in the range of 0.4 to 5.9 µM (Table I). On the other hand, pol. β was moderately influenced, and the range of the IC_{50} values was 14 to 43 µM, except for C_{14}-SQMG. The activity of pol. α was inhibited potently by the C_{14-18}-SQMG/C_{14-18}-SQDG, and the IC_{50} values (the doses that resulted in inhibition of 50% of the activities) were in the range of 0.4 to 5.9 µM (Table I). On the other hand, pol. β was moderately influenced, and the range of the IC_{50} values was 14 to 43 µM, except for C_{14}-SQMG. The IC_{50} value for pol. α of stearic acid alone was 12 µM, while those of C_{18-α}-SQMG and C_{18-β}-SQMG were 1.6 and 2.1 µM, respectively. The effectiveness of stearic acid (group I) was increased more than 6-fold by conjugation of sulfoquinovosylylacylglyceride (group I & II & III). The data concerning the chain size of the fatty acid shown in Table I suggested that inhibition is mostly dependent on the fatty acid effect, and the sulfoquinovosylylacylglyceride (group I & II & III) in the SQMG/SQDG may increase the inhibitory activity.

As shown in Fig. 2, the C_{18-α}-SQMG/C_{18-α}-SQDG also inhibited TdT, and had a moderate inhibitory effect on HIV-1 reverse transcriptase, but hardly affected the activities of DNA polymerases such as *E. coli* DNA polymerase I, T4 DNA polymerase and *Taq* DNA polymerase, or DNA metabolic enzymes such as T7 RNA polymerase, T4 polynucleotide and deoxyribonuclease I. All of the other SQMG/SQDG with shorter fatty acids showed similar effects (data not shown).

**Modes of DNA polymerase α and β inhibition by synthetic SQMG/SQDG** To investigate the mechanisms of

---

**Table I**

| DNA polymerase α activity (%) | DNA polymerase β activity (%) |
|-----------------------------|-----------------------------|
| Sulfolipid (C18-SQG) / Fatty acid (C18) (µM) | Sulfolipid (C18-SQG) / Fatty acid (C18) (µM) |
| (A) | (B) |
| 0 | 0 |
| 0.05 | 0.05 |
| 0.1 | 0.1 |
| 0.5 | 0.5 |
| 1 | 1 |
| 5 | 5 |
| 10 | 10 |
| 20 | 20 |
| 40 | 40 |
| 60 | 60 |
| 80 | 80 |
| 100 | 100 |

---

**Fig. 2.** Inhibition of activities of DNA polymerase α (A) and β (B) by C_{18-α}-SQMG/C_{18-α}-SQDG and stearic acid (C_{18}). Each mixture contained 0.05 units of enzyme. DNA polymerase activity (5000 cpm) in the absence of C_{18-α}-SQMG/C_{18-α}-SQDG or stearic acid was taken as 100%. The compounds tested and symbols used are as follows: C_{18-α}-SQMG, ; C_{18-α}-SQDG, ; C_{18-β}-SQMG, ; C_{18-β}-SQDG, ; C_{18} (stearic acid), .
inhibition of pol. α and pol. β by SQMG/SQDG, kinetic analyses were performed (Table II). Poly(dA)/oligo(dT)\textsubscript{12-18} (A/T = 2/1) and dTTP were used as DNA template-primer and nucleotide substrate, respectively. Double reciprocal plots of the results showed that inhibition of pol. α by C\textsubscript{18}-α-SQMG/C\textsubscript{18}-α-SQDG was non-competitive with both the DNA template-primer and dTTP substrate, since there were no changes in apparent $K_m$ for both were decreased in the presence of C\textsubscript{18}-α-SQMG or C\textsubscript{18}-α-SQDG. On the other hand, the inhibitory effects of C\textsubscript{18}-α-SQMG and C\textsubscript{18}-α-SQDG on pol. β were competitive with either the template-primer or the substrate. In the case of the template-primer, the apparent $V_{max}$ of either C\textsubscript{18}-α-SQMG/C\textsubscript{18}-α-SQDG was unchanged, whereas an increase in $K_m$ was observed in the presence of C\textsubscript{18}-α-SQMG or C\textsubscript{18}-α-SQDG. Similar results were observed with α-SQMG/α-SQDG with the other fatty acids and β-configured SQMG/SQDG tested, which could inhibit these DNA polymerase activities; non-competitive to pol. α and competitive to pol. β with either the DNA template-primer or the substrate (data not shown). These results were consistent with those for the natural products, SQDGs from fern\textsuperscript{11} and long chain fatty acids\textsuperscript{4,6} described previously. These results indicated that each of the SQMG/SQDG may bind or interact to a domain distinct from the nucleotide substrate or template-binding sites on pol. α. On the other hand, each of the SQMG/SQDG must directly interact with both the nucleotide substrate- and template-binding sites of pol. β.

The inhibition constant ($K_i$) values of C\textsubscript{18}-α-SQMG for pol. α, obtained from Dixon plots, were found to be 0.7 and 2.7 µM for template-primer and nucleotide substrate respectively, corresponding to the final concentration in the reaction mixture (Table II). Similarly, the $K_i$ values for pol. β were 3.8 and 13 µM, respectively. For both enzymes, the $K_i$ values for template-primer were smaller than those for nucleotide substrate, suggesting that either C\textsubscript{18}-α-SQMG or C\textsubscript{18}-α-SQDG binds or interacts with the template-primer binding site on the DNA polymerases with greater affinity than their nucleotide substrate binding site. Scatchard plot analyses indicated that each of the SQMG/SQDG and the template-primer interacted one to one on pol. α. Similar results were obtained for the interaction of each of the SQMG/SQDG and the nucleotide substrate (data not shown).

When NP-40 was added to the reaction mixture at a concentration of 0.05%, only the inhibition of pol. β was reversed (Table III), indicating that each of the C\textsubscript{18}-α-
Novel Group of DNA Polymerase Inhibitors

SQMG/C_{18}-α-SQDG may bind to and interact with the hydrophobic region on pol. β protein, probably around the template-binding site.\textsuperscript{6, 8) The sulfolipids may bind more tightly to the pol. α protein in a different manner. We also tested whether an excessive amount of protein or nucleic acid (i.e., BSA at 80 µg/ml or 40 µM poly(rC), respectively) could prevent the inhibitory effect of each SQMG/SQDG, to determine whether their effects resulted from non-specific adhesion to the polymerases, or selective binding to specific sites (Table III). Neither BSA nor poly(rC) influenced the effects of the C_{18}-α-SQMG/C_{18}-α-SQDG on pol. α or pol. β, suggesting that the binding to the polymerases occurs selectively. That is, each of the SQMG/SQDG appeared to inhibit these enzymes selectively, for example by binding to the hydrophobic region.

### Table II. Kinetic Analysis of the Inhibitory Effects of C_{18}-α-SQMG/C_{18}-α-SQDG on the Activities of DNA Polymerase α and β, as a Function of the DNA Template-primer Dose and the dTTP Substrate Concentration

| Enzyme | Template-primer\textsuperscript{c,d} | Nucleotide Substrate\textsuperscript{c,d} | Sulfolipid conc. (µM) | $K_m$ (µM) | $V_{max}$ (pmol/h) | $K_i$ (µM) | Inhibitory mode\textsuperscript{a} |
|--------|---------------------------------|---------------------------------|----------------------|------------|------------------|------------|------------------|
| Pol. α | Template-primer | 0 | 2.1 | 200 | 0.7 | Non-competitive |
|        |                   | 1 | 2.1 | 160 | | |
|        |                   | 2 | 2.1 | 100 | | |
|        |                   | 3 | 2.1 | 67  | | |
|        | Nucleotide Substrate | 0 | 1.3 | 230 | 2.7 | Non-competitive |
|        |                   | 1 | 1.3 | 190 | | |
|        |                   | 2 | 1.3 | 140 | | |
|        |                   | 3 | 1.3 | 90  | | |
| Pol. β | Template-primer | 0 | 1.7 | 145 | 3.8 | Competitive |
|        |                   | 5 | 3.3 | | | |
|        |                   | 10 | 6.3 | | | |
|        |                   | 15 | 7.9 | | | |
|        | Nucleotide Substrate | 0 | 0.9 | 38  | 13  | Competitive |
|        |                   | 5 | 1.0 | | | |
|        |                   | 10 | 1.3 | | | |
|        |                   | 15 | 2.7 | | | |
| Pol. α | Template-primer | 0 | 2.1 | 200 | 0.2 | Non-competitive |
|        |                   | 0.2 | 2.1 | 100 | | |
|        |                   | 0.4 | 2.1 | 56  | | |
|        |                   | 0.6 | 2.1 | 40  | | |
|        | Nucleotide Substrate | 0 | 1.3 | 230 | 0.6 | Non-competitive |
|        |                   | 0.2 | 1.3 | 170 | | |
|        |                   | 0.4 | 1.3 | 100 | | |
|        |                   | 0.6 | 1.3 | 56  | | |
| Pol. β | Template-primer | 0 | 1.7 | 145 | 5.0 | Competitive |
|        |                   | 10 | 5.0 | | | |
|        |                   | 20 | 9.8 | | | |
|        | Nucleotide Substrate | 0 | 0.9 | 38  | 36  | Competitive |
|        |                   | 10 | 1.3 | | | |
|        |                   | 20 | 1.4 | | | |
|        |                   | 40 | 3.3 | | | |

\textsuperscript{a) From Lineweaver Burk plot.}
\textsuperscript{b) From Dixon plot.}
\textsuperscript{c) i.e., poly(dA)/oligo(dT)\textsubscript{12-18}.}
\textsuperscript{d) i.e., dTTP.}

Effects of synthetic SQMG/SQDG on cultured mammalian cells To investigate the tumoricidal effects of each of the SQMG/SQDG, the human stomach cancer cell line
NUGC-3 was tested in vitro. As expected, some of the C_{14-18}-SQMG/C_{14-18}-SQDG prevented proliferation of the cell line; the inhibition curves are shown in Fig. 4. In this experiment, β-SQDG/β-SQMG with saturated fatty acids, and SQDG/SQMG with unsaturated fatty acids were not tested for the reason mentioned above. The results shown in Fig. 4 indicated that the synthetic SQMG had potent growth-inhibitory effects on this cancer cell line. Unexpectedly, none of the SQDG tested showed such an inhibitory effect. The LD_{50} concentrations of these SQMG were in the range of about 18 to 35 \mu M for the α-configurations and about 20 to 38 \mu M for the β-configurations. The configuration had little effect on the cell growth inhibition. As in the case of the effects on pol. α and pol. β, stronger inhibitory effects were observed with longer chain fatty acid in the SQMG (Table I). The LD_{50} value of the most potent compound tested, C_{18}-SQMG, was approximately 20 \mu M for NUGC-3 cells, and complete inhibition occurred at about 30 \mu M. Since the IC_{50} values of the C_{18}-SQMG were about 2 \mu M for pol. α, and approximately 15 \mu M for pol. β (Table I), the LD_{50} value was 10 times the IC_{50} value for pol. α and similar to the LD_{50} value for pol. β. Comparison of the data shown in Table I and Fig. 4 indicated that both in vivo cell growth inhibition and in vitro enzyme inhibition were reduced in parallel with the chain size of the fatty acid in the SQMG. For polymerase inhibition, SQDG was more effective than SQMG (Fig. 2), but the SQDG showed no effect on cell growth, suggesting that SQDG cannot penetrate into the cells.

### DISCUSSION

We have been screening for new DNA polymerase inhibitors for use in analyzing the structure and function of mammalian DNA polymerases, in order to understand the...
their precise roles in vivo, and to develop drug design strategies for cancer chemotherapy agents. These inhibitors should be not only useful molecular tools for analyzing the polymerases, but also candidates as cancer chemotherapy agents. Subsequently, we synthesized many sulfoquinovosylacylglycerols, including steroids and their derivatives (Hanashima et al., in preparation). Some of the synthetic SQMG or SQDG compounds inhibited the activities of the DNA polymerases in the concentration ranges of 0.4 to 9.1 \( \mu M \) for pol. \( \alpha \) and 14 to 43 \( \mu M \) for pol. \( \beta \) (Table I, Fig. 3). SQMG/SQDG showed markedly stronger inhibitory effects than aphidicolin on pol. \( \alpha \) (Mizushina et al., unpublished data). We should also emphasize that SQMG/SQDG suppressed the activities of pol. \( \beta \) in vitro to the same extent as dideoxyTTP, a well-known potent pol. \( \beta \) inhibitor. Due to their strong inhibitory effects, these SQMG/SQDG could be useful as DNA polymerase-specific inhibitors in studies to determine the precise roles of each polymerase. As shown in Fig. 1A, the molecules of the SQMG/SQDG (group I & II & III & IV) consist of one/two saturated long alkyl chains (group IV) as a hydrophobic moiety and one 6-sulfated glucopyranoside ring (group I & II) as a hydrophilic site, bound to a glyceride moiety (group III) by ether linkages.

In this study, we demonstrated that not only the chain size of the fatty acid, but also the sulfate moiety of the glycerolipids was important for the inhibitory activity of the synthetic SQMG/SQDG. Sulfoquinovose (group I & II), glucosylglyceride (group II & III), acylglycerol (group III & IV), sulfoquinovosylglyceride (group I & II & III) and glucosylglycerol, which lack the sulfate moiety (group II & III & IV), showed no inhibitory effects. The 6-sulfo-D-quinovosylglycerol (group I & II & III & IV) could be replaced by a 6-sulfo-D-fucosylglycerol or 6-sulfo-D-rhamnosylglycerol, so the species of the sugar appeared to have little effect on the inhibition. The molecular mode of the inhibition seems to depend on the chain size of the fatty acids. Since the 6-sulfo-D-quinovosylglyceride (group I & II & III) itself showed no inhibitory effect on the polymerases, the inhibitory effects of these compounds may depend on the binding of the fatty acid ester region to the polymerases, and the 6-sulfo-D-quinovosylglyceride in the SQMG/SQDG appeared to strengthen the inhibition.

Further investigations of the structure of the binding site on both polymerases and their modes of binding are necessary. Based on the results of cross-linkage studies and NMR analyses, we previously reported the mode of binding between pol. \( \beta \) and long chain fatty acids, which are major part(s) of the SQMG/SQDG involved in inhibition of pol. \( \beta \) activity. Pol. \( \beta \) is the smallest known DNA polymerase in animal cells, with a molecular mass of 39 kDa, and its structure is highly conserved among mammals. This protein has a modular two-domain structure, with apparent flexibility within a protease-sensitive region between residues 82–86, which separates the two domains, i.e., an N-terminal domain fragment (8 kDa), which retains binding affinity for ssDNA, and a C-terminal domain fragment (31 kDa) with reduced DNA polymerase activity. The fatty acids bound to pol. \( \beta \) at the N-terminal 8 kDa domain, where they competed with the DNA template-primer molecule. One molecule of each of the agents at the fatty acid region competed with one molecule of template DNA, and subsequently interfered with the binding of template-primer DNA to one molecule of 8 kDa domain, indicating that the 8 kDa domain fragment bound to the fatty acids as a 1:1 complex. Therefore, the fatty acids in the SQMG/SQDG may also fit into the binding site. The solution structure of the 8 kDa domain fragment with the fatty acids has been determined in more detail by multi-dimensional NMR.

The binding interactions with the fatty acids were mapped to one face of the 8 kDa domain fragment by characterizing the backbone \(^1\)H and \(^15\)N chemical shift changes. In the 8 kDa domain fragment with the fatty acids, the structure that forms the interaction interface included helix-1, helix-2, helix-4, a turn (residues from 48 to 51) and residues adjacent to an \( \Omega \)-type loop connecting helix-1 and helix-2. Since the methyl end of the fatty acids appears to bind to L11, H51 and T79 of the interface on the amino acid sheets of the 8 kDa domain fragment and the carboxyl end interacts with the K35 site, the distance between the methyl and carboxyl ends might be important for tight binding. Only the shifted cross-peaks of L11 and T79 were significantly influenced by the length of the carbon chain. Longer fatty acids could bind to the fragment more tightly. In the action of the SQMG/SQDG on pol. \( \beta \), the fatty acid interaction interface on the amino acid sheets of the 8 kDa domain fragment must be mostly the same as that in the case of fatty acids in SQMG/SQDG. Since the 6-sulfo-D-quinovose in the SQMG/SQDG bound to the carboxyl end of the fatty acids, it must be located not at the sites of L11, H51 and T79, but at the K35 site. The sulfate moiety may strengthen the binding to the surface of the 8 kDa domain fragment, resulting in a further shift of the cross-peak of K35. Although the influence of SQMG/SQDG on pol. \( \alpha \) remains to be determined in future studies, the interaction of the fatty acids and pol. \( \beta \) suggested that they may be useful for analyzing the structure and function of the polymerases, and in our continuing screening for SQMG/SQDG with potent inhibitory activity against polymerases. Similar experiments should be performed using pol. \( \alpha \), because the inhibition of cell growth by the SQMG may be due to the inhibition of both polymerases. Unfortunately, pol. \( \alpha \) is too large for NMR analysis at present.

We were also interested in developing cancer chemotherapy agents using these inhibitors. Therefore, we investigated the effects of these compounds on a human cancer
cell line (NUGC-3) in culture. The SQMG showed potent growth inhibitory effects on the cancer cells, but none of the SQDG tested had such an effect (Fig. 4). SQMG inhibited both polymerase activity and cell growth in a dose-dependent manner (Figs. 2 and 4). SQDG were completely inactive to the cells, although their in vitro effects were stronger than those of SQMG, suggesting that the SQDG cannot penetrate into the cells. The LD₅₀ concentrations of these C₁₄₋₁₈-SQMG were in the range of about 20 to 40 μM, which are realistic from the viewpoint of drug design. Stronger inhibitory effects were observed with longer chain size of the fatty acid in the SQMG (Fig. 4). Both in vivo and in vitro inhibitory effects were dose-dependently reduced in parallel with the chain size of the fatty acid in the SQMG. The in vivo inhibition must therefore depend on the strength of binding between the fatty acid ester region and the polymerase. The sulfoquinovosylacylglyceride (group I & II & III) in the SQMG appears to strengthen the binding. The binding strength depends on the tertiary structure of the SQMG, for the following reasons; the lack of growth inhibition by the fatty acid alone, the lack of a free carboxyl end in SQMG, although fatty acids in which the carboxyl end was chemically modified lost the binding effect, and the fact that each SQMG tested showed stronger inhibitory effects than the corresponding fatty acid alone. Some of the SQMG should be tested as anti-cancer agents. Drug design will be possible by investigating the tightness of the binding between the SQMG and pol β. Based on information available from the NMR structure, computer-simulation of the conformational changes in pol β should also be useful for this purpose.

ACKNOWLEDGMENTS

We are grateful to Dr. S. Yoshida of Nagoya University and Dr. A. Matsukage of Japan Women’s University for preparing calf DNA polymerase τ and rat DNA polymerase β, respectively, and for valuable discussions concerning inhibitors. This work was supported in part by grants to Y. M. from the Mochida Memorial Foundation for Medical and Pharmaceutical Research and from the Uehara Memorial Foundation. This work also partly supported by Grants-in-Aid to Y. M. and F. S. from the Ministry of Education, Science, Sports and Culture of Japan (No. 12780442 and 12660103, respectively).

Received June 19, 2000/Revised July 19, 2000/Accepted July 25, 2000

REFERENCES

1) Kornberg, A. and Baker, T. “DNA Replication,” Chap. 6 “Eukaryotic DNA Poly merases,” pp. 197–225 (1992). W. H. Freeman and Co., New York.
2) Burgers, P. M. J. Eukaryotic DNA polymerases in DNA replication and DNA repair. Chromosoma, 107, 218–227 (1998).
3) Johnson, R. E., Prakash, S. and Prakash, L. Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, pol η. Science, 283, 1001–1004 (1999).
4) Mizushima, Y., Tanaka, N., Yagi, H., Kurosawa, T., Onoue, M., Seto, H., Horie, T., Aoyagi, N., Yamaoka, M., Matsukage, A., Yoshida, S. and Sakaguchi, K. Fatty acids selectively inhibit eukaryotic DNA polymerase activities in vitro. Biochim. Biophys. Acta, 1308, 256–262 (1996).
5) Mizushima, Y., Yagi, H., Tanaka, N., Kurosawa, T., Seto, H., Katsumi, K., Onoue, M., Ishida, H., Iseki, A., Nara, T., Morohashi, K., Horie, T., Onoue, M., Narusawa, M., Aoyagi, N., Takami, K., Yamaoka, M., Inoue, Y., Matsukage, A., Yoshida, S. and Sakaguchi, K. Screening of inhibitor of eukaryotic DNA polymerases produced by microorganisms. J. Antibiot. (Tokyo), 49, 491–492 (1996).
6) Mizushima, Y., Yoshida, S., Matsukage, A. and Sakaguchi, K. The inhibitory action of fatty acids on DNA polymerase β. Biochim. Biophys. Acta, 1336, 509–521 (1997).
7) Mizushima, Y., Matsukage, A. and Sakaguchi, K. The biochemical inhibition mode of bredinin-5′-monophosphate on DNA polymerase β. Biochim. Biophys. Acta, 1403, 5–11 (1998).
8) Mizushima, Y., Takahashi, N., Hanashima, L., Koshino, H., Esumi, Y., Uzawa, J., Sugawara, F. and Sakaguchi, K. Lucidienic acid O and lactone, new terpene inhibitors of eukaryotic DNA polymerases from a basidiomycete, Ganoderma lucidum. Bioorg. Med. Chem., 7, 2047–2052 (1999).
9) Mizushima, Y., Hanashima, L., Yamaguchi, T., Takemura, M., Sugawara, F., Saneyoshi, M., Matsukage, A., Yoshida, S. and Sakaguchi, K. A mushroom fruiting body-inducing substance inhibits activities of replicative DNA polymerases. Biochem. Biophys. Res. Commun., 249, 17–22 (1998).
10) Mizushima, Y., Tanaka, N., Kitamura, A., Takami, I., Ikeda, M., Takemura, M., Sugawara, F., Arai, T., Matsukage, A., Yoshida, S. and Sakaguchi, K. The inhibitory effect of novel triterpenoid compounds, forimelic acids, on DNA polymerase β. Biochem. J., 330, 1325–1332 (1998).
11) Mizushima, Y., Watanabe, I., Ohta, K., Takemura, M., Sahara, H., Takahashi, N., Gasa, S., Sugawara, F., Matsukage, A., Yoshida, S. and Sakaguchi, K. Studies on inhibitors of mammalian DNA polymerase α and β. Biochem. Pharmacol., 55, 537–541 (1998).
12) Togashi, H., Mizushima, Y., Takemura, M., Sugawara, F., Koshino, H., Esumi, Y., Uzawa, J., Kumagai, H., Matsukage, A., Yoshida, S. and Sakaguchi, K. 4-Hydroxy-17-methylincosterol, an inhibitor of DNA polymerase-α activity and the growth of human cancer cells in vitro. Biochem. Pharmacol., 56, 583–590 (1998).
13) Mizushima, Y., Watanabe, I., Togashi, H., Hanashima, L., Takemura, M., Ohta, K., Sugawara, F., Koshino, H., Esumi, Y., Uzawa, J., Matsukage, A., Yoshida, S. and Sakaguchi, K. An ergosterol peroxide, a natural product that selec-
tively enhances the inhibitory effect of linoleic acid on DNA polymerase β. *Biol. Pharm. Bull.*, 21, 444–448 (1998).

14) Ohta, K., Mizushima, Y., Hirata, N., Takemura, M., Sugawara, F., Matsukage, A., Yoshida, S. and Sakaguchi, K. Action of a new mammalian DNA polymerase inhibitor, sulfoquinovosyldiacylglycerol. *Biol. Pharm. Bull.*, 22, 111–116 (1999).

15) Ohta, K., Mizushima, Y., Hirata, N., Takemura, M., Sugawara, F., Matsukage, A., Yoshida, S. and Sakaguchi, K. A 5′-monophosphate form of breedin selectively inhibits the activities of mammalian DNA polymerases in vitro. *Int. J. Mol. Med.*, 1, 83–90 (1998).

16) Mizushima, Y., Ueno, T., Goto, Y., Isobe, Y., Sako, M., Fujita, T., Hirota, K., Hayashi, H. and Sakaguchi, K. Carboxylflavins, novel inhibitors of Taq DNA polymerase. *Int. J. Mol. Med.*, 2, 283–286 (1998).

17) Mizushima, Y., Ohkubo, T., Date, T., Yamaguchi, T., Saneyoshi, M., Sugawara, F. and Sakaguchi, K. Mode analysis of a fatty acid molecule binding to the N-terminal 8 kDa domain of DNA polymerase β. *J. Biol. Chem.*, 274, 25599–25607 (1999).

18) Tanaka, N., Kitamura, A., Mizushima, Y., Sugawara, F. and Sakaguchi, K. Fomitellic acid, triterpenoid inhibitors of eukaryotic DNA polymerases from a basidiomycete, *Fomitella fraxinea*. *J. Nat. Prod.*, 61, 193–197 (1998).

19) Gustafson, K. R., Cardellina, J. H., II, Fuller, R. W., Weislow, O. S., Kiser, R. F., Snader, K. M., Patterson, G. M. L. and Boyd, M. R. α-D-xylofuranosyladenine 5′-triphosphate on DNA-dependent RNA polymerase I and II from cherry salmon (*Oncorhynchus masou*). *J. Biochem.*, 97, 1385–1389 (1985).

20) Soltes, D. A. and Uhlenbeck, O. C. Isolation and characterization of two mutant forms of T4 polynucleotide kinase. *Biochemistry*, 29, 2983–2990 (1988).

21) Sahara, H., Ishikawa, M., Takahashi, N., Ohtani, S., Sato, N., Gasa, S., Akino, T. and Kikuchi, K. In vivo anti-tumour effect of 3′-sulphonoquinovosyl 1′-monocacylglyceride isolated from sea urchin (*Strongylocentrotus intermedius*) intestine. *Br. J. Cancer*, 75, 324–332 (1997).

22) Takehayashi, S., Sato, N., Takayama, S., Ichimiya, S., Hyakumachi, N. and Kikuchi, K. Establishment of apoptotic and immunoaffinity-purified DNA polymerase α and DNA primase complex from calf thymus. *Biochem. Biophys. Acta.*, 950, 263–273 (1988).

23) Nakayama, C. and Saneyoshi, M. Inhibitory effects of 9-β-D-xylofuranosyladenine 5′-triphosphate on DNA-dependent RNA polymerase I and II from cherry salmon (*Oncorhynchus masou*). *J. Biochem.*, 97, 1385–1389 (1985).

24) Lu, B. C. and Sakaguchi, K. An endo-exonuclease from meiotic tissues of the basidiomycete *Coprinus cinereus*. *J. Biol. Chem.*, 257, 11332–11339 (1982).

25) Lu, B. C. and Sakaguchi, K. An endo-exonuclease from meiotic tissues of the basidiomycete *Coprinus cinereus*. *J. Biol. Chem.*, 257, 21060–21066 (1991).

26) Takehayashi, S., Sato, N., Takayama, S., Ichimiya, S., Hyakumachi, N. and Kikuchi, K. Establishment of apoptotic and immunoaffinity-purified DNA polymerase α and DNA primase complex from calf thymus. *Biochem. Biophys. Acta.*, 950, 263–273 (1988).

27) Soltes, D. A. and Uhlenbeck, O. C. Isolation and characterization of two mutant forms of T4 polynucleotide kinase. *Biochemistry*, 29, 2983–2990 (1988).

28) Lu, B. C. and Sakaguchi, K. An endo-exonuclease from meiotic tissues of the basidiomycete *Coprinus cinereus*. *J. Biol. Chem.*, 257, 11332–11339 (1982).

29) Takehayashi, S., Sato, N., Takayama, S., Ichimiya, S., Hyakumachi, N. and Kikuchi, K. Establishment of apoptotic and immunoaffinity-purified DNA polymerase α and DNA primase complex from calf thymus. *Biochem. Biophys. Acta.*, 950, 263–273 (1988).